Publication: 2410

CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers
      QxMD      Google Scholar   
Citation:
J Clin Oncol vol 34 (23) 2736-2742
Year:
2016
Type:
Manuscript
Funding:
NCTN
Endpoint:
Primary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
ppub
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Book Volume:
5
Parents:
693  
Children:
None
Program:
OGC
Primary Committee:
GI
Sec. Committees:
   
Pharmas:
80403-Bristol Myers/Enzinger; Sanofi Aventis; and Pfizer ECOG 1206- None  
Grants:
U10 CA021115, U10 CA031946, U10 CA180821, P30 CA008748, U10 CA180850, P30 CA060553, U10 CA180882, U10 CA180820, U10 CA180867, P30 CA006927  
Corr. Author:
 
Authors:
                         
Networks:
CA043, CA824, LAPS-CT018, LAPS-IL036, LAPS-MA036, LAPS-NY016, LAPS-OH007   
Study
CALGB-80403
Multiple Studies, or Legacy Studies in Alliance Study:
ECOG-1206
Phases:
2, 2
Keywords:
Gic12, ORIGINAL REPORTS, Gastrointestinal Cancer